Magnesium therapy in infants with postneonatal apnea

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Clinical Chemistry

Background:

• Idiopathic postneonatal apnea is a sudden, unexpected breathing cessation occurring after hospital discharge.
• Limited data exists on the clinical and laboratory findings during these acute apneic episodes.
• This study investigates physical and laboratory parameters, including magnesium deficiency, in infants with postneonatal apnea.

Purpose of the Study:

• To retrospectively analyze the physical and clinical laboratory findings in infants experiencing idiopathic postneonatal apnea.
• To investigate the role of magnesium deficiency and the impact of magnesium therapy on apnea recurrence.

Main Methods:

• Retrospective analysis of 20 infants with idiopathic postneonatal apnea.
• Assessment of physical and laboratory findings, including investigations for magnesium deficiency.
• Comparison of outcomes between infants receiving prolonged magnesium (Mg) therapy (≥5 days) and those receiving short-term or no Mg therapy (<5 days).

Main Results:

• Apneic episodes occurred around 48 days of age, were unpredictable, transient, and self-limited.
• Severe cases presented as shock with apnea, bradycardia, respiratory distress, and/or neuromuscular irritability, accompanied by acidosis, hemoconcentration, and hyperkalemia.
• Mg-treated infants (n=7) showed no recurrence of apnea requiring resuscitation, while 6 of 13 Mg-untreated infants were readmitted for apnea.

Conclusions:

• Severe idiopathic postneonatal apnea can manifest as a shock-like, self-limited episode with a tendency to recur.
• Magnesium therapy is associated with a significant reduction in recurrent apnea episodes.
• Findings are supported by a parallel study showing reduced recurrent apnea in Mg-treated premature infants (p < 0.001).